Cite
HARVARD Citation
Harbeck, N. et al. (n.d.). ADAPTcycle – adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk HR+/HER2- early breast cancer. Breast. pp. S133-. [Online].